CompletedPhase 2/3

Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment

Egypt6 participantsStarted 2020-04-01

Plain-language summary

Suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate targeted therapeutic delivery to the choroidal and retinal structures than intravitreal injection

Who can participate

Age range47 Years – 52 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients diagnosed as VKH serous retinal detachment in the acute phase whom BCVA is not improving after 2 weeks from starting systemic steroids. Exclusion Criteria: * recent intraocular surgery. * patients refuse to participate in the study. * media opacity and other causes of serous retinal detachment than VKH.

What they're measuring

Best Corrected Visual Acuity (LogMAR units)

Timeframe: 6 months after injection

Trial details

NCT IDNCT05031143

SponsorBenha University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-02-20

View on ClinicalTrials.gov More Vogt Koyanagi Harada Disease trials